These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 33722086)

  • 1. Antimicrobial and antibiofilm activities of meropenem loaded-mesoporous silica nanoparticles against carbapenem-resistant
    Memar MY; Yekani M; Ghanbari H; Nabizadeh E; Vahed SZ; Dizaj SM; Sharifi S
    J Biomater Appl; 2021 Oct; 36(4):605-612. PubMed ID: 33722086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biocompatibility, cytotoxicity and antibacterial effects of meropenem-loaded mesoporous silica nanoparticles against carbapenem-resistant
    Memar MY; Yekani M; Ghanbari H; Shahi S; Sharifi S; Maleki Dizaj S
    Artif Cells Nanomed Biotechnol; 2020 Nov; 48(1):1354-1361. PubMed ID: 33236938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibacterial and biofilm-inhibitory effects of vancomycin-loaded mesoporous silica nanoparticles on methicillin-resistant staphylococcus aureus and gram-negative bacteria.
    Memar MY; Yekani M; Farajnia S; Ghadiri Moghaddam F; Nabizadeh E; Sharifi S; Maleki Dizaj S
    Arch Microbiol; 2023 Mar; 205(4):109. PubMed ID: 36884153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct determination of carbapenem-resistant Enterobacteriaceae and Pseudomonas aeruginosa from positive blood cultures using laser scattering technology.
    Idelevich EA; Hoy M; Knaack D; Görlich D; Peters G; Borowski M; Becker K
    Int J Antimicrob Agents; 2018 Feb; 51(2):221-226. PubMed ID: 29111432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Selective Culture Medium for Screening Carbapenem Resistance in
    Nordmann P; Fournier C; Poirel L
    Microb Drug Resist; 2021 Oct; 27(10):1355-1359. PubMed ID: 33877916
    [No Abstract]   [Full Text] [Related]  

  • 6. Risk factors and clinical significance of bacteremia caused by Pseudomonas aeruginosa resistant only to carbapenems.
    Lee CH; Su TY; Ye JJ; Hsu PC; Kuo AJ; Chia JH; Lee MH
    J Microbiol Immunol Infect; 2017 Oct; 50(5):677-683. PubMed ID: 26188977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dissemination of carbapenem-resistant Pseudomonas aeruginosa isolates and their susceptibilities to ceftolozane-tazobactam in Germany.
    Kresken M; Körber-Irrgang B; Korte-Berwanger M; Pfennigwerth N; Gatermann SG; Seifert H;
    Int J Antimicrob Agents; 2020 Jun; 55(6):105959. PubMed ID: 32325200
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Pahlavanzadeh F; Kalantar-Neyestanaki D; Motamedifar M; Mansouri S
    Yale J Biol Med; 2020 Mar; 93(1):29-34. PubMed ID: 32226332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic and antibiofilm activity of the antimicrobial peptide P5 against carbapenem-resistant Pseudomonas aeruginosa.
    Martinez M; Gonçalves S; Felício MR; Maturana P; Santos NC; Semorile L; Hollmann A; Maffía PC
    Biochim Biophys Acta Biomembr; 2019 Jul; 1861(7):1329-1337. PubMed ID: 31095945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new carbapenem drug dosage metric for carbapenem usage and correlation with carbapenem resistance of Pseudomonas aeruginosa.
    Hirayama S; Yasui K; Murakami H; Kosugi T; Sakamoto M; Hanai Y; Matsuo K; Miyazaki T; Ishii Y; Nishizawa K; Tateda K
    J Infect Chemother; 2018 Dec; 24(12):949-953. PubMed ID: 30268412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between Biofilm Formation and Antimicrobial Resistance in Carbapenem-Resistant
    Cho HH; Kwon KC; Kim S; Park Y; Koo SH
    Ann Clin Lab Sci; 2018 May; 48(3):363-368. PubMed ID: 29970441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of in vitro synergistic antibiotic interaction between fosfomycin and nonsusceptible antimicrobials in carbapenem-resistant Pseudomonas aeruginosa.
    Avery LM; Sutherland CA; Nicolau DP
    J Med Microbiol; 2019 Jun; 68(6):893-897. PubMed ID: 31050629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of heteroresistance to polymyxin B among carbapenem-susceptible and -resistant Pseudomonas aeruginosa.
    Hermes DM; Pormann Pitt C; Lutz L; Teixeira AB; Ribeiro VB; Netto B; Martins AF; Zavascki AP; Barth AL
    J Med Microbiol; 2013 Aug; 62(Pt 8):1184-1189. PubMed ID: 23699064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation and study of antimicrobial activity of nanoliposomal meropenem against Pseudomonas aeruginosa isolates.
    Zahra MJ; Hamed H; Mohammad RY; Nosratollah Z; Akbarzadeh A; Morteza M
    Artif Cells Nanomed Biotechnol; 2017 Aug; 45(5):975-980. PubMed ID: 27322561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Staggering the administration of polymyxin B and meropenem in time-kill against carbapenem-resistant Enterobacteriaceae exhibiting a wide range of meropenem MICs.
    Kulengowski B; Clark JA; Burgess DS
    Diagn Microbiol Infect Dis; 2019 Mar; 93(3):261-264. PubMed ID: 30344066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of sub-MIC level of meropenem and ciprofloxacin against extensive drug-resistant (XDR) Pseudomonas aeruginosa isolates of diabetic foot ulcer patients.
    Srivastava P; Sivashanmugam K
    Infect Genet Evol; 2021 Aug; 92():104824. PubMed ID: 33774177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of ceftolozane/tazobactam, alone and in combination with colistin, against multidrug-resistant Pseudomonas aeruginosa in an in vitro biofilm pharmacodynamic model.
    Gómez-Junyent J; Benavent E; Sierra Y; El Haj C; Soldevila L; Torrejón B; Rigo-Bonnin R; Tubau F; Ariza J; Murillo O
    Int J Antimicrob Agents; 2019 May; 53(5):612-619. PubMed ID: 30682497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mesoporous silica nanoparticles decorated with polycationic dendrimers for infection treatment.
    González B; Colilla M; Díez J; Pedraza D; Guembe M; Izquierdo-Barba I; Vallet-Regí M
    Acta Biomater; 2018 Mar; 68():261-271. PubMed ID: 29307796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro evaluation of meropenem-vaborbactam against clinical CRE isolates at a tertiary care center with low KPC-mediated carbapenem resistance.
    Kinn PM; Chen DJ; Gihring TM; Schulz LT; Fox BC; McCreary EK; Lepak AJ
    Diagn Microbiol Infect Dis; 2019 Mar; 93(3):258-260. PubMed ID: 30344065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of Meropenem-Vaborbactam against Pseudomonas aeruginosa and Acinetobacter baumannii in a Neutropenic Mouse Thigh Infection Model.
    Sabet M; Tarazi Z; Griffith DC
    Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30323049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.